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Introduction: Infectious keratitis following penetrating keratoplasty is a common postoperative complication.
Intensive topical and systemic treatments do not always prevent the risk of graft failure. In this report we
demonstrate the beneficial anti-microbial effect of corneal collagen cross-linking in a late-onset, sight-threatening,
corneal graft ulcer.
Case presentation: A 57-year old Caucasian man underwent penetrating keratoplasty in his left eye, due to corneal
bullosa after cataract extraction surgery. Twelve months after the penetrating keratoplasty, he visited our emergency
service complaining of burning and foreign body sensation in his operated eye. Slit-lamp examination revealed a
central, round-shaped ulcer of the graft. Due to poor response to the intensive topical antibiotic therapy, corneal
collagen cross-linking was applied 3 days after admission, in an attempt to control the infection. Cultures indicated the
predominance of methicillin-resistant Staphylococcus aureus infection. Five days after corneal collagen cross-linking
treatment, the epithelium was completely re-epithelized, while the transparency of the transplanted cornea was
gradually restored within the 12-month follow-up period. No relapses occurred.
Conclusion: Corneal collagen cross-linking seems to be a safe and effective therapeutic alternative in resistant cases of
infectious keratitis following penetrating keratoplasty.
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Infectious keratitis after penetrating keratoplasty (PK) is a
common, sight-threatening complication both in the early
and the late postoperative period. Post-PK infectious kera-
titis is associated with a dramatic decrease in visual acuity
and graft decompensation [1]. Unfortunately, intensive
topical and systemic medications do not always prevent
graft failure and/or permanent visual impairment [1].
Corneal collagen cross-linking (CxL) is a minimally in-
vasive technique that combines the use of riboflavin and
ultraviolet A (UV-A) radiation, enhancing the rigidity of
the corneal tissue [2]. Despite the fact that the primary in-
dication for CxL is the management of ectatic disorders
[3], recent publications indicate that it might be used as a
therapeutic alternative in a series of other corneal diseases
like infectious keratitis and corneal bullosa [4-9].* Correspondence: labiris@usa.net
1Department of Ophthalmology, University Hospital of Alexandroupolis,
68100 Dragana, Alexandroupolis, Greece
2Eye Institute of Thrace, Alexandroupolis, Alexandroupolis, Greece
© 2014 Labiris et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orIn this report, we demonstrate the successful thera-
peutic management of a resistant infectious keratitis fol-
lowing penetrting keratoplasty by means of CxL.
Case presentation
We describe the case of a 57-year-old Caucasian man
with uneventful medical history who underwent com-
plicated phacoemulsification cataract surgery (posterior
capsular rupture with anterior vitrectomy) and intraocu-
lar lens insertion at the sulcus of his left eye, in a private
medical center. He was referred to our department 1
year after his initial cataract operation due to endothelial
insufficiency and elevated intraocular pressure (IOP) in
his operated eye. At presentation he presented best cor-
rected visual acuity (BCVA) of counting fingers (CF) at 1
meter and, IOP of 28mmHg despite intensive topical
treatment of timolol–dorzolamide fixed combination
(Cosopt®, Vianex AE, Greece) twice a day, brimonidine
(Alphagan®, Allergan Pharmaceuticals Ltd, Ireland) twice
a day and latanoprost (Xalatan®, Pfizer Hellas A.E.,
Greece) once per day. Slit-lamp biomicroscopy revealedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Graft ulcer at presentation.
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sented BCVA 20/20 and IOP of 14mmHg without any
medication.
He was admitted and underwent uneventful PK in his
left eye, followed by an uneventful trabeculectomy with
mitomycin, 3 months later. Within 6 months after the
PK his diurnal IOP measurements had been stabilized
(mean IOP: 15mmHg) without any glaucoma medi-
cation, while his BCVA remained CF at 1 meter due to
non-reversible damage to his optic nerve by the un-
controlled IOP in the period following the cataract
operation. His corneal graft was clear with no signs of
rejection, and he was tapering loteprednol (Lotemax®,
Kite Hellas EPE, Greece) drops.
Twelve months following the PK and prior to any
suture removal, he urgently visited our emergency ser-
vice, complaining of burning and foreign body sensation
in the operated eye. His visual acuity had decreased to
hand motion and slit-lamp biomicroscopy revealed con-
junctival injection and a central, round-shaped ulcer ofFigure 2 Anterior segment optical coherence tomography of the ulcethe graft, extending from 3 to 5 o’-clock area, with a size
of 3 to 3.5mm (Figure 1). Moreover, anterior-segment op-
tical coherence tomography demonstrated severe thinning
of the graft at the site of the ulcer with associated local
Descemet-membrane detachment (Figure 2). Gram and
Giemsa stains, as well as cultures of the affected corneal tis-
sue were performed, while two sutures at the site of the
ulcer, and two more at the contralateral site, were removed.
The sight-threatening clinical picture and the positive re-
sults for cocci from the stains suggested the introduction of
intensive topical antibiotic therapy that included fortified
5% vancomycin (Voncon®, Lilly, Nederland B.V.) alternating
with fortified 5% ceftazidime (Solvetan®, GlaxoSmithKline
ABEE, Greece), every 30 minutes. However, despite the in-
tensive antibiotic treatment, the clinical picture continued
to deteriorate with visualization of inflammatory cells in
the anterior chamber and destabilization of the graft-
recipient cornea connection at the site of the ulcer. Mean-
while, the stains indicated a multimicrobial infection and
the cultures isolated methicillin-resistant Staphylococcus
aureus (MRSA). Based on the clinical and laboratory data,
CxL was attempted 3 days after the emergency admission
in order to control the infection and stabilize the border
between the graft and the recipient cornea.
CxL treatment was applied as follows: proparacaine
hydrochloride 0.5% drops were instilled for topical anes-
thesia. De-epithelialization was performed by means of a
hockey knife, in a circular area that surrounded the ulcer
and at least 2mm of healthy corneal tissue. After de-
epithelialization, a mixture of 0.1% riboflavin in 20%
dextran solution was instilled to his cornea (two drops
every 2 minutes) until the stroma was completely pene-
trated and the aqueous was stained yellow. In our case
we could visualize the change in the color of the aque-
ous about 14 minutes after the instillation had begun.
The UV-A radiation source that was used was the UV-X
(Peschke Meditrade, Cham, Switzerland). In detail, anr.
Figure 3 Imaging of the affected area (5th day post-collagen
cross-linking).
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30 minutes by UV-A light with a wavelength of 370nm
and an irradiance of 3mW/cm2, while instillation of
riboflavin drops (one drop every 2 minutes) was con-
tinued during irradiation. Moreover, a balanced salt solu-
tion was applied every 6 minutes to moisten his cornea.
After irradiation, a soft contact lens (Day & Night; CIBA
Vision, Corp, Duluth, GA, USA) was applied.
Within 5 days after the CxL, significant improvement
of the clinical picture was observed (Figure 3), the
epithelium was completely re-epithelized, and the topi-
cal treatment was modified to moxifloxacin (Vigamox®,
Alcon Laboratories AEBE, Greece) drops, four times a
day. The topical antibiotic treatment was continued for
1 month following CxL treatment. The final postopera-
tive examination revealed minor scarring at the site of
the ulcer with strong connection between the graft and
recipient cornea (Figure 4). No relapses occurred for a
total postoperative period of 12 months.Figure 4 Anterior segment optical coherence tomography 1 month pDiscussion
It is well established that the activation of riboflavin,
during the CxL process, is accompanied by release of re-
active oxygen species. These oxygen species combined
with the antimicrobial activity of UV-A radiation itself
can induce deoxyribonucleic acid (DNA) damage to a
series of pathogens [10]. Martins et al. [5] demonstrated
the antimicrobial properties of CxL against common
pathogens. Moreover, it is already known that post-CxL
corneas demonstrate increased tissue resistance to mi-
crobial enzymatic digestion [2].
An extensive literature review revealed a series of re-
ports on successful CxL application in cases of infectious
keratitis. Iseli et al. [6] described several cases of bacterial
keratitis, in which CxL treatment inhibited the corneal
melting process. In their study, Kozobolis et al. [4] pre-
sented a case series of bullous keratopathy combined with
corneal ulcer that was successfully treated with CxL. In
our case, the infectious ulcer was developed on a corneal
transplant. The clinical examination and the Gram stains
suggested a multimicrobial infection, while the cultures
isolated MRSA. It is known that Staphylococcus aureus is
among the most common causes of late microbial kera-
titis, following PK [11,12], mainly due to the long-term
use of topical steroids to prevent rejection [13,14]. There-
fore, intensive topical antibiotic therapy, including fortified
5% vancomycin drops, was initiated upon admission. Des-
pite that fact, the clinical picture continued to deteriorate
for the following 2 days. Therefore, CxL treatment was ap-
plied, in an attempt to: a) control the infection, b) prevent
corneal perforation, and c) prevent the destabilization of
the graft-recipient corneal bond. Since no guidelines have
been introduced for CxL in infectious keratitis, we modi-
fied the standard protocol prior to UV-A irradiation, as
follows: a) de-epithelialization was attempted only around
the affected area, and b) we continued UV-A irradiation
immediately when aqueous was stained yellow. However,
a full 30 minutes of UV-A irradiation was applied. Theost-collagen cross-linking.
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deteriorating clinical picture was completely reversed, in-
fection was controlled and the graft survived. The authors
cannot predict whether the conventional topical antibiotic
treatment alone would produce the same favorable out-
come, however, we are confident that CxL had a beneficial
synergetic effect without any evident negative impact on
the graft.
Conclusions
To the best of our knowledge, this is the first case of suc-
cessful application of CxL for the treatment of infectious
keratitis on a corneal graft. The results of our report are
encouraging, regarding the potential therapeutic applica-
tion of CxL in patients with sight-threatening, post-PK in-
fectious keratitis. Further studies are necessary to explore
the potential beneficial impact of the proposed therapeutic
procedure and provide the necessary data for the develop-
ment of a valid therapeutic protocol.
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